Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer

NCT ID: NCT01686958

Last Updated: 2020-02-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-03-13
• Study Completion Date: 2019-06-11

Brief Summary

This study is to evaluate that the magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system is safe and feasible to ablate prostate tissue in men with localized prostate cancer.

Detailed Description

Profound Medical Inc. has developed a novel technology called the MRI-guided transurethral ultrasound therapy system. The technology is developed for patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.

The treatment is conducted completely within an MRI suite, which enables real-time temperature images of the heated region to be acquired as the ultrasonic treatment is delivered. Using MRI thermometry during treatment, dynamic temperature feedback control over the intensity of the ultrasound beams and rotation of the Ultrasound Applicator can shape the pattern of thermal coagulation accurately and precisely in the prostate gland, thereby reducing the risk of possible damage to important surrounding anatomy such as the rectum, urinary sphincters, neurovascular bundles and pelvic bone. This coagulation method, therefore, has the potential to have lower complication rates than conventional therapies.

Conditions

Prostate Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

MR-Guided Transurethral US Ablation

MR-Guided Transurethral US Ablation of Prostate Tissue

Group Type: EXPERIMENTAL

MR-Guided Transurethral US Ablation of Prostate Tissue

Intervention Type: DEVICE

The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.

Interventions

MR-Guided Transurethral US Ablation of Prostate Tissue

The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.

Intervention Type: DEVICE

Other Intervention Names

Prostate Ablation Device: PAD-105

Eligibility Criteria

Inclusion Criteria

• Male, age ≥65
• Patient with low-risk, early-stage organ-confined prostate cancer (Stage T1c or T2a, N0, M0).
• Gleason score 6 (3+3)
• Prostate-specific antigen (PSA) ≤ 10 ng/ml
• Eligible for MR imaging (DOC-10252)
• Meets the following criteria on pre-treatment transrectal ultrasound imaging:

1. No cysts or calcifications > 1.0 cm in size

2. No evidence of extraprostatic extension or seminal vesicle invasion

3. Overall prostate size less than 5 cm in sagittal length and less than 7 cm in diameter

• Biopsy confirmed adenocarcinoma of the prostate, performed at least 6 weeks prior to and no more than 6 months prior to the scheduled treatment.
• Eligible for General Anesthesia, as defined in American Society of Anesthesiologists (ASA)
• Normal rectal anatomy and rectal mucosa on digital rectal examination

Exclusion Criteria

• Bleeding disorder
• Abnormal coagulation and current anticoagulant therapy.
• Acute or chronic Urinary Tract Infection
• Interest in future fertility
• History of allergy relevant medication or other
• History of any other malignancy other than skin cancer
• Patients with peripheral arterial disease with intermittent claudication or Leriches Syndrome
• Prior treatment of the prostate gland
• Prior treatment with 5 alpha reductase inhibitor allowed (not as prostate cancer treatment or prevention) as long as drug has been stopped for minimum 3 months
• History of any major rectal or pelvic surgery
• History of ulcerative colitis or other chronic inflammatory conditions affecting rectum
• History of documented clinical prostatitis requiring therapy within previous 6 months
• History of urethral and bladder outlet disorders, including urethral stricture disease, urethral diverticulae, bladder neck contracture, urethral fistulae which had required prior urethrotomy, urethral stenting, urethroplasty or chronic indwelling urethral catheter
• Patients with artificial urinary sphincter or any penile implant (metallic or non-metallic)
• Neurologic bladder disorders
• Untreated bladder stones
• History of acute urinary retention
• Confirmed or suspected bladder cancer
• Urinary sphincter abnormalities
• Active untreated gross hematuria for any cause
• Post Void Residual (PVR) bladder volume > 250 mL
• Obstructing median lobe enlarged out of proportion to the rest of the prostate and protruding significantly into the bladder

• Minimum Eligible Age: 65 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Profound Medical Inc.

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Joseph Chin, MD

Role: PRINCIPAL_INVESTIGATOR

London Health Science Center

James Relle, MD

Role: PRINCIPAL_INVESTIGATOR

William Beaumont Hospitals

Ryan Berglund, MD

Role: PRINCIPAL_INVESTIGATOR

The Cleveland Clinic

Heinz P Schlemmer, MD

Role: PRINCIPAL_INVESTIGATOR

German Cancer Research Center

Locations

William Beaumont Hospital

Royal Oak, Michigan, United States

London Health Science Centre

London, Ontario, Canada

German Cancer Research Center (DKFZ)

Heidelberg, , Germany

Countries

United States; Canada; Germany

References

Chin JL, Billia M, Relle J, Roethke MC, Popeneciu IV, Kuru TH, Hatiboglu G, Mueller-Wolf MB, Motsch J, Romagnoli C, Kassam Z, Harle CC, Hafron J, Nandalur KR, Chronik BA, Burtnyk M, Schlemmer HP, Pahernik S. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial. Eur Urol. 2016 Sep;70(3):447-55. doi: 10.1016/j.eururo.2015.12.029. Epub 2016 Jan 6.

Reference Type: DERIVED

PMID: 26777228 (View on PubMed)

Other Identifiers

DOC-10246

Identifier Type: -

Identifier Source: org_study_id